Coeptis Therapeutics (NASDAQ:ZSQR – Get Free Report) issued its earnings results on Thursday. The company reported ($0.28) earnings per share for the quarter, Zacks reports. Coeptis Therapeutics had a negative return on equity of 92.29% and a negative net margin of 810.04%.
Coeptis Therapeutics Stock Performance
Shares of Coeptis Therapeutics stock traded up $0.27 on Thursday, reaching $4.16. 398,778 shares of the stock were exchanged, compared to its average volume of 260,849. The company has a quick ratio of 3.25, a current ratio of 3.25 and a debt-to-equity ratio of 0.01. Coeptis Therapeutics has a twelve month low of $3.77 and a twelve month high of $21.41. The firm has a market capitalization of $213.95 million, a price-to-earnings ratio of -1.65 and a beta of -0.20. The business has a 50 day moving average price of $8.56 and a two-hundred day moving average price of $10.86.
Analyst Ratings Changes
Separately, Wall Street Zen downgraded Coeptis Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, June 13th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has an average rating of “Sell”.
Hedge Funds Weigh In On Coeptis Therapeutics
A number of institutional investors have recently bought and sold shares of ZSQR. State Street Corp boosted its holdings in shares of Coeptis Therapeutics by 35.0% in the 4th quarter. State Street Corp now owns 26,830 shares of the company’s stock valued at $382,000 after acquiring an additional 6,962 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Coeptis Therapeutics by 12.6% during the fourth quarter. Geode Capital Management LLC now owns 42,097 shares of the company’s stock worth $600,000 after purchasing an additional 4,721 shares during the last quarter. Marshall Wace LLP purchased a new position in shares of Coeptis Therapeutics during the fourth quarter worth $259,000. Finally, Steward Partners Investment Advisory LLC lifted its position in Coeptis Therapeutics by 100.0% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 5,000 shares of the company’s stock valued at $71,000 after purchasing an additional 2,500 shares during the period. 13.88% of the stock is owned by hedge funds and other institutional investors.
Coeptis Therapeutics Company Profile
Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.
Read More
- Five stocks we like better than Coeptis Therapeutics
- Asian Market Circuit Breakers Hit Stocks, Not AI Demand
- Riot Platforms Re-Wires the Ledger for a $9B AI Power Play
- Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?
- Joby’s Defense Pivot Accelerates With $500M Resonant Sciences Deal
Receive News & Ratings for Coeptis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coeptis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
